TMCnet News

Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
[December 18, 2014]

Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014


Research and Markets (http://www.researchandmarkets.com/research/mqcxzk/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong productportfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned:

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Sanofi
  • Eli Lilly and Company
  • Viralytics Ltd.
  • Genentech, Inc.
  • MedImmune, LLC
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • Lentigen Corporation
  • Amorfix Life Sciences Ltd.
  • Piramal Enterprises Limited
  • Celltrion, Inc.
  • Astellas Pharma Inc.
  • BioMarin Pharmaceutical Inc.
  • Richter Gedeon Nyrt.
  • Astex Pharmaceuticals, Inc.
  • Genmab A/S
  • Cyclacel Pharmaceuticals Inc.
  • Celgene Corporation
  • Onyx Pharmaceuticals, Inc.
  • Bayer AG
  • Incyte Corporation
  • Merck KGaA
  • 4SC AG
  • Celldex Therapeutics, Inc.
  • Immunomedics, Inc.
  • TG Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/mqcxzk/chronic



[ Back To TMCnet.com's Homepage ]